Fusion protein · developed by Keros Therapeutics
Rinvatercept (KER-065) is an agent administered subcutaneously and studied in Duchenne muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07704099 | Phase 2 | Duchenne Muscular Dystrophy | Recruiting | KROS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Duchenne Muscular Dystrophy
Updated Oct 18, 2026. Something wrong or missing? Report it on the KROS page.
See KROS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KROS catalysts and pipeline →